Madrigal Pharmaceuticals - MDGL Stock Forecast, Price & News

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Madrigal Pharmaceuticals in the last twelve months. There are currently 2 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MDGL shares.
View MDGL analyst ratings or view top-rated stocks.

11 Wall Street analysts have issued twelve-month target prices for Madrigal Pharmaceuticals' stock. Their MDGL share price forecasts range from $151.00 to $390.00. On average, they anticipate the company's stock price to reach $294.75 in the next twelve months. This suggests a possible upside of 22.2% from the stock's current price.
View analysts price targets for MDGL or view top-rated stocks among Wall Street analysts.

Madrigal Pharmaceuticals' stock was trading at $290.25 at the start of the year. Since then, MDGL shares have decreased by 16.9% and is now trading at $241.27.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, May 8th 2023.
View our MDGL earnings forecast.

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) issued its quarterly earnings data on Thursday, February, 23rd. The biopharmaceutical company reported ($4.98) EPS for the quarter, missing analysts' consensus estimates of ($4.61) by $0.37.

ETFs with the largest weight of Madrigal Pharmaceuticals (NASDAQ:MDGL) stock in their portfolio include Virtus LifeSci Biotech Clinical Trials ETF (BBC), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Invesco DWA Healthcare Momentum ETF (PTH), Invesco Nasdaq Future Gen 200 ETF (QQQS), iShares U.S. Pharmaceuticals ETF (IHE), Principal Healthcare Innovators ETF (BTEC) and Alger Mid Cap 40 ETF (FRTY).

Based on aggregate information from My MarketBeat watchlists, some companies that other Madrigal Pharmaceuticals investors own include Achillion Pharmaceuticals (ACHN), Exelixis (EXEL), Ayala Pharmaceuticals (ADXS), Viking Therapeutics (VKTX), Sangamo Therapeutics (SGMO), Amarin (AMRN), CRISPR Therapeutics (CRSP), Intercept Pharmaceuticals (ICPT), Sarepta Therapeutics (SRPT) and Gilead Sciences (gild).

Madrigal Pharmaceuticals trades on the NASDAQ under the ticker symbol "MDGL."

Madrigal Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Avoro Capital Advisors LLC (9.71%), Avidity Partners Management LP (2.51%), Susquehanna International Group LLP (0.00%), Geode Capital Management LLC (1.38%), Artisan Partners Limited Partnership (1.24%) and Armistice Capital LLC (1.22%). Insiders that own company stock include Bay City Capital Llc, Brian Joseph Lynch, Fred B Craves, Remy Sukhija and Richard S Levy.
View institutional ownership trends.

Shares of MDGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MDGL stock can currently be purchased for approximately $241.27.

Madrigal Pharmaceuticals (NASDAQ:MDGL) has a market capitalization of $4.38 billion. The biopharmaceutical company earns $-295,350,000.00 in net income (profit) each year or ($17.23) on an earnings per share basis.

Madrigal Pharmaceuticals' mailing address is 200 BARR HARBOR DRIVE SUITE 400, WEST CONSHOHOCKEN PA, 19428. The official website for the company is www.madrigalpharma.com. The biopharmaceutical company can be reached via phone at (267) 824-2827, via email at ir@madrigalpharma.com, or via fax at 781-274-8228.